A Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer

JAMA: The Journal of the American Medical Association

Volumn 273, Issue 4, 1995, Pages 289-294

  Gann, Peter H ^a   Hennekens, Charles H ^b   Stampfer, Meir J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0028801975     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03520280035036     Document Type: Article

References (28)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
2. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients. J Urol. 1989;141:1076-1083.
3. Mettlin C, Jones G, Averett H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup. CA Cancer J Clin. 1993;43:42-46.
4. American Urological Association Executive Committee Report, 1992. Baltimore, Md: American Urological Association; May 1992.
5. Mettlin C, Jones GW, Murphy GP. Trends in prostate care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993;43:83-91.
6. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980; 14:29-35.
7. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251-254.
8. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE for the Prostate Patient Outcomes Research Team. An assessment of radical prostatectomy. JAMA. 1993;269:2633-2636.
9. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846-852.
10. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate specific antigen. J Urol. 1990; 143:1146-1152.
11. Babaian RJ, Mettlin C, Kane R, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonograph. Cancer. 1992;69:1195-1200.
12. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
13. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
14. Liedtke RJ, Batjer JD. Measurement of prostate-specific antigen by radioimmunoassay. Clin Chem. 1984;30:649-652.
15. Hortin GL, Bahnson RR, Daft M, Chan K-M, Catalona WJ, Ladenson JH. Differences in values obtained with 2 assays of prostate specific antigen. J Urol. 1988;139:762-765.
16. Graves HCB, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for PSA. J Urol. 1990;144:1516-1522.
17. Catalona WJ. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med. 1987;147:361-363.
18. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: 242-248.
19. Helzlsouer KJ, Newby J, Comstock GW. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Cancer Epidemiol Biomarkers Prev. 1992;1:537-540.
20. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
21. Murphy GP. Report on the American Urologie Association/American Cancer Society Scientific Seminar on the Detection and Treatment of EarlyStage Prostate Cancer. CA Cancer J Clin. 1994; 44:91-95.
22. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191.
23. Morrison AS. Screening in Chronic Disease. 2nd ed. New York, NY: Oxford University Press; 1992.
24. Walter SD, Day NE. Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol. 1983;118:865-886.
25. Task Force appointed to the Conference of Deputy Ministers of Health. Cervical cancer screening programs: the Walton Report. Can Med Assoc J. 1976;114:1003-1033.
26. Walsh PC. Why make an early diagnosis of prostate cancer. J Urol. 1992;147:853-854.
27. Ruckle HC, Klee GG, Oesterling JE. Prostatespecific antigen. Mayo Clin Proc. 1994;69:59-68.
28. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer. JAMA. 1994;271:368-374.